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Br J Pharmacol. 2019;1–15.Background and Purpose: Adenosine is a local mediator that regulates a number of
physiological and pathological processes via activation of adenosine A1‐receptors. The
activity of adenosine can be regulated at the level of its target receptor via drugs that
bind to an allosteric site on the A1‐receptor. Here, we have investigated the species
and probe dependence of two allosteric modulators on the binding characteristics
of fluorescent and nonfluorescent A1‐receptor agonists.
Experimental Approach: A Nano‐luciferase (Nluc) BRET (NanoBRET) methodology
was used. This used N‐terminal Nluc‐tagged A1‐receptors expressed in HEK293T cells
in conjunction with both fluorescent A1‐receptor agonists (adenosine and NECA ana-
logues) and a fluorescent antagonist CA200645.
Key Results: PD 81,723 and VCP171 elicited positive allosteric effects on
the binding affinity of orthosteric agonists at both the rat and human A1‐receptors that
showed clear probe dependence. Thus, the allosteric effect on the highly selective par-
tial agonist capadenoson was much less marked than for the full agonists NECA, aden-
osine, and CCPA in both species. VCP171 and, to a lesser extent, PD 81,723, also
increased the specific binding of three fluorescent A1‐receptor agonists in a species‐
dependent manner that involved increases in Bmax and pKD.
Conclusions and Implications: These results demonstrate the power of the
NanoBRET ligand‐binding approach to study the effect of allosteric ligands on the
binding of fluorescent agonists to the adenosine A1‐receptor in intact living cells. Fur-
thermore, our studies suggest that VCP171 and PD 81,723 may switch a proportion
of A1‐receptors to an active agonist conformation (R*).- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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‐G‐ABEA); ABA, (ABA‐X‐BY630); ABEA, (ABEA‐X‐BY630); CA200645, xanthine amine congener‐β‐alanine,β‐
o‐6‐[[2‐(4‐chlorophenyl)‐1,3‐thiazol‐4‐yl]methylsulfanyl]‐4‐[4‐(2‐hydroxyethoxy)phenyl]pyridine‐3,5‐dicarbonitrile;
X, 1,3‐dipropyl‐8‐cyclopentylxanthine; MRS1220, N‐[9‐chloro‐2‐(furan‐2‐yl)‐[1,2,4]triazolo[1,5‐c]quinazolin‐5‐yl]‐
o)adenosine; Nluc, Nano‐luciferase; Nluc‐A1R, Nanoluc‐labelled A1 adenosine receptor; PD 81,723, (2‐amino‐4,5‐
thanone; VCP171, (2‐amino‐4‐(3‐(trifluoromethyl)phenyl)thiophen‐3‐yl)(phenyl)methanone; VCP746, 4‐(5‐amino‐4‐
‐N‐(6‐(9‐((2R,3R,4S,5R)‐3,4‐dihydroxy‐5‐(hydroxylmethyl)tetrahydro‐furan‐2‐yl)‐9H‐purin‐6‐ylamino)hexyl)
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What is already known
• Adenosine is a local mediator that regulates
physiological processes via activation of adenosine A1‐
receptors.
• Agonist activity can be regulated by drugs that bind to
an allosteric site on the A1‐receptor.
What does this study adds
• This study demonstrates the power of fluorescent ligand
NanoBRET approaches to study allosterism in cells.
• Positive allosteric modulators can switch a proportion of
A1‐receptors to an active agonist‐binding conformation.
What is the cl inical s ignif icance
• This study provides insights into allosteric mechanisms
that may provide new opportunities for drug discovery.Adenosine is a local reactive metabolite that has a major role in reg-
ulating a number of physiological and pathological processes includ-
ing inflammation, hypoxia, and cardiovascular regulation (Fredholm,
Ijzerman, Jacobson, Linden, & Müller, 2011). Adenosine acts via four
specific GPCRs, which have been denoted adenosine A1‐, A2A‐, A2B‐,
and A3‐receptors (Fredholm et al., 2011). The A1‐ and A3‐receptors
preferentially couple to Gi/o proteins and have an inhibitory action
on adenylyl cyclase activity whilst the A2A‐ and A2B‐receptors couple
to Gs proteins and stimulate cAMP formation (Fredholm et al., 2011;
Müller & Jacobson, 2011). The crystal structures of the A2A‐receptor
in both antagonist (Jaakola et al., 2008) and agonist (Xu et al., 2011)
bound conformations have been determined, and very recently,
the structure of the adenosine A1‐receptor has also been solved
(Cheng et al., 2017; Glukhova et al., 2017), including an adenosine‐
bound A1‐receptor in complex with a Gi‐protein (Draper‐Joyce
et al., 2018).
Numerous selective agonists and antagonists for each adenosine
receptor subtype are now available for the study of receptor func-
tion (see Fredholm et al., 2011; Müller & Jacobson, 2011). In the
case of the adenosine A1‐receptor, a number of compounds have
previously undergone evaluation for cardiovascular disease indica-
tions such as paroxysmal supraventricular tachycardia, atrial fibrilla-
tion, and angina pectoris (Müller & Jacobson, 2011). At the present
time, the A1‐receptor partial agonist neladenoson is undergoing
clinical trial for heart failure (Meibom et al., 2017). However, the
ubiquitous distribution of adenosine receptors in the body can often
limit therapeutic application because of the effects of adenosine
ligands on the same receptor in a different tissue or cell type (Müller
& Jacobson, 2011).
Activation of cell surface adenosine receptors by endogenous
adenosine requires it to be available at the extracellular surface of
cells. Extracellular adenosine can rise as a consequence of several
pathways (Fredholm et al., 2011). It can be formed intracellularly fol-
lowing various metabolic processes and be exported from cells via
membrane transporters, or it can be formed in the extracellular space
from adenine nucleotides released from cells. Once ATP or ADP is
released, the nucleotide is broken down by nucleoside triphosphate
diphosphohydrolases (e.g., CD39) and then ecto‐5′‐nucleotidase
(CD73) to adenosine (Fredholm et al., 2011; Knapp et al., 2012). The
intricacies of localized extracellular release of adenine nucleotides
and subsequent production of adenosine following CD73 activity has
recently provided insights into the role of adenosine A1‐receptors in
mediating localized analgesia in animals and humans (Goldman et al.,
2010; Sowa, Voss, & Zylka, 2010; Street & Zylka, 2011). In addition,
there is increasing evidence that adenosine A1‐receptors may be
involved in promoting angiogenesis and the release of VEGF in
response to local hypoxia and neoplasia (Clark et al., 2007; Merighi
et al., 2009).
From the foregoing argument, it is clear that localized regulation
of adenosine production may have important therapeutic implications.One way in which the activity of endogenous adenosine can be
subtly regulated at the level of its target receptor is via drugs that
bind to an allosteric site on the receptor. These allosteric modulators
act to enhance or inhibit the binding of adenosine to its receptor
binding site (the orthosteric site) and/or change the resulting
functional response (Hill, May, Kellam, & Woolard, 2014). Some of
the earliest allosteric modulators, such as PD 81,723, were
discovered for the adenosine A1‐receptor (Bruns & Fergus, 1990;
Bruns et al., 1990; Göblyös & IJzerman, 2011; Kimatrai‐Salvador,
Baraldi, & Romagnoli, 2012). VCP171, [(2‐amino‐4‐(3‐(trifluoro-
methyl)phenyl)thiophen‐3‐yl)(phenyl)methanone], has also recently
been described as a novel 2‐amino‐3‐benzoylthiophene positive
allosteric modulator (Aurelio et al., 2009, 2010; Valant et al.,
2010; Vincenzi et al., 2014) and has been investigated in a rat
model of neuropathic pain (Imlach, Bhola, May, Christopoulos, &
Christie, 2015).
The potential for allosteric enhancers to provide highly localized
augmentation of adenosine actions on target receptors is well
established (Hill et al., 2014). However, the in vivo actions of allosteric
regulators have not been extensively investigated, and there is a need
to evaluate the potential for these small molecules to augment specific
actions of adenosine in particular organs or cell types in a whole ani-
mal setting. Some limited success has been achieved in vivo with PD
81,723. Activation of adenosine A1‐receptors has been shown to pro-
tect against renal ischaemia/reperfusion injury in experimental animals
(Lee & Emala, 2000; Lee, Gallos, Nasr, & Emala, 2004; Park et al.,
2012). However, despite the high homology between the species
homologues of the A1‐receptor, there is evidence for species
COOPER ET AL. 3BJPdifferences in the affinity of certain adenosine receptor ligands (Müller
& Jacobson, 2011; Szymańska et al., 2016).
The aim of the present study was to compare the effect of PD
81,723 and VCP171 on the human and rat adenosine A1‐receptors
expressed in HEK293T cells and to evaluate the extent to which they
exhibit probe and species dependence in a whole cell environment. To
do this, we made use of the recently established Nano‐luciferase
(Nluc) BRET methodology (NanoBRET; Stoddart, Johnstone, et al.,
2015; Stoddart, Vernall, Briddon, Kellam, & Hill, 2015) using
N‐terminal Nluc‐tagged A1‐receptors in conjunction with fluorescent
A1‐receptor agonists and antagonists (Stoddart, Johnstone, et al.,
2015). These fluorescent ligands included the xanthine amine congener
based antagonist ligand CA200645 (Corriden, Kilpatrick, Kellam,
Briddon, & Hill, 2014; Stoddart, Johnstone, et al., 2015) and fluorescent
A1‐agonists based on adenosine (ABA‐X‐BY630; Middleton et al.,
2007; May, Self, Briddon, & Hill, 2010) or NECA (ABEA‐X‐BY630,
Cordeaux, Briddon, Alexander, Kellam, & Hill, 2008; Stoddart,
Johnstone, et al., 2015; BY630‐X‐(D)‐A‐(D)‐A‐G‐ABEA; Stoddart,
Vernall, et al., 2015).2 | METHODS
2.1 | Constructs, cell lines, and cell culture
Human and rat Nluc‐labelled adenosine A1‐receptor (Nluc‐A1R) con-
structs were generated as previously described by Stoddart,
Johnstone, et al. (2015). In brief, the full‐length sequence of Nluc
luciferase from the pNL1.1 vector (Promega) was amplified and
fused in‐frame with the membrane signal sequence of the 5‐HT3A
membrane localization signal sequence (pcDNA3.1 sig‐Nluc; Soave,
Stoddart, Brown, Woolard, & Hill, 2016). This was fused to the
full‐length human or rat sequence of the adenosine A1‐receptor
(with the methionine start signal removed) to the 3′ end of the
sig‐Nluc in pcDNA3.1. The resulting fusion protein contained a
Gly‐Ser linker between the Nluc open reading frame and the human
or rat A1 open reading frame. This resulted in the human and rat
Nluc‐A1R constructs.2.2 | Cultured cells
HEK293T cells (ATCC Cat# CRL‐3216, RRID:CVCL_0063) were
maintained in DMEM supplemented with 2 mM L‐glutamine and
10% fetal calf serum at 37°C 5% CO2. Once 70–80% confluent, cells
were dislodged from the flask surface by gentle shaking after incu-
bation in 0.25% trypsin and collected following centrifugation at
1000× g for 5 min. Cells were then seeded at 2–5 × 10,000 cells
cm‐2. Mixed population human Nluc‐A1‐AR and rat Nluc‐A1‐AR cell
lines were generated using Fugene HD (Promega) according to the
manufacturer's instructions, and cells were then subjected to
1 mg/mL G418‐selection pressure for 2 weeks.2.3 | BRET human and rat Nluc‐A1R ligand‐binding
assays
The fluorescent antagonist saturation, competition‐binding, allosteric
modulator binding cooperativity, and the fluorescent agonist satura-
tions in the presence/absence of allosteric modulator assays were per-
formed on the stably transfected HEK293T cells expressing human or
rat Nluc‐A1R. The cells were seeded 24 hr before experimentation in
white walled, poly‐D‐lysine coated 96‐well microplates (Thermo Scien-
tific, Loughborough, UK) at a density of 25,000 cells per well.
The medium was replaced with HEPES‐buffered saline solution
(145 nM NaCl, 5 mM KCl, 1.7 mM CaCl2, 1 mM MgSO4, 10 mM
HEPES, 2 mM sodium pyruvate, 1.5 mM NaHCO3, 10 mM D‐glucose,
pH 7.2–7.45), with the required concentration of fluorescent ligand,
competing ligand, and/or allosteric modulator. For each experiment,
ligands were added simultaneously, and the 96‐well plate was incu-
bated for 1 hr at 37°C (no CO2). Following this, the Nluc substrate
furimazine (Promega) was added to give a final concentration of
10 μM and then incubated for 5 min at 37°C. For all experiments,
the luminescence and resulting BRET were measured using the
PHERAstar FS plate reader (BMG Labtech) using filtered light emis-
sions at 460 nm (80 nm bandpass) and >610 nm (longpass) at room
temperature. The raw BRET ratio was calculated by dividing the
>610 nm emission by the 460 nm emission.
2.4 | Data analysis
Data were presented and analysed using Prism 7 software (GraphPad
software, San Diego, CA, USA).
Saturation‐binding curves were simultaneously fitted to obtain
the total and non‐specific components using the following equation:
BRET ratio ¼ Bmax × B½ 
B½  þ KD þ M × B½ ð Þ þ Cð Þ;
where Bmax is the maximal level of specific binding, [B] is the concen-
tration of fluorescent ligand in nM, KD is the equilibrium dissociation
constant in nM, M is the slope of the linear non‐specific binding com-
ponent, and C is the y‐axis intercept.
Competition NanoBRET data was fitted using a one‐site sigmoidal
competition curve given by the following equation:
%uninhibited binding ¼ 100 − 100 × A
n½ ð Þ
An½  þ ICn50
 þ NS;
where [A] is the concentration of competing drug, NS is the non‐
specific binding, n is the Hill coefficient, and IC50 is the concentration
of ligand required to inhibit 50% of the specific binding of the fluores-
cent ligand.
The IC50 values from competition‐binding curves were used to
calculate the Ki of the unlabelled ligands using the Cheng–Prusoff
equation:
Ki ¼ IC50
1þ L½ 
KD
;
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the dissociation constant of the fluorescent ligand in nM. The KD
values used were obtained from the saturation‐binding experiments.
Pooled fluorescent agonist saturation assays obtained in the pres-
ence and absence of a fixed concentration of allosteric modulator
were simultaneously fitted to the following equation:
BRET ratio ¼ Bmax × B½ 
B½  þ KD þ M × B½ ð Þ þ Cð Þ:
The slope of the non‐specific binding component M was kept
constant (equivalent to the slope of the binding curve obtained in
the presence of 1 μM DPCPX in the same experiments), and a
partial F test was used to determine whether a significantly better
fit was obtained with individual parameters for Bmax and KD for each
curve (control vs. that obtained in the presence of VCP171 or
PD 81,723) when compared with sharing the parameters
between curves.
2.5 | Statistical analysis
The statistical analyses in this study comply with the recommenda-
tions on experimental design and analysis in pharmacology (Curtis
et al., 2018). Statistical significance was determined by one‐way
ANOVA followed by Tukey's post hoc test, partial F test, or unpaired
Student's t test. In all cases, differences were considered significant at
P < 0.05. All statistical analysis was performed using GraphPad Prism
7.03 (RRID:SCR_002798). In all cases, individual experiments were
performed in triplicate, and statistical analysis was performed on the
data obtained from five or six repeat experiments.
2.6 | Materials
Adenosine receptor ligands: adenosine (Cat# A9251), 5′‐N‐ethylcar-
boxamidoadenosine (NECA; Cat# E2387), and (2‐amino‐4,5‐di-
methylthiophen‐3‐yl)(3‐(trifluoromethyl)phenyl)methanone (PD 81,723;
Cat#P1123) were purchased from Sigma‐Aldrich (Gillingham, UK). 1,3‐Di-
propyl‐8‐cyclopentylxanthine (DPCPX; C101), 2‐chloro‐N6‐cyclopen-
txyladenosine (CCPA; Cat# C7938), and N‐[9‐chloro‐2‐(furan‐2‐yl)‐[1,
2,4]triazolo[1,5‐c]quinazolin‐5‐yl]‐2‐phenylacetamide (MRS1220; Cat#
M228) were purchased from Tocris Bioscience (Bristol, UK).
(2‐Amino‐4‐(3‐(trifluoromethyl)phenyl)thiophen‐3‐yl)(phenyl)metha-
none (VCP171) and 4‐(5‐amino‐4‐benzoyl‐3‐(3‐(trifluoromethyl)phenyl)
thiophen‐2‐yl)‐N‐(8‐(9‐((2R,3R,4S,5R)‐3,4‐dihydroxy‐5‐(hydroxylmethyl)
tetrahydro‐furan‐2‐yl)‐9H‐purin‐6‐ylamino)hexyl)benzamide (VCP746)
were synthesized as previously described by Aurelio et al. (2009) and
Valant et al. (2014) respectively. 2‐Amino‐6‐[[2‐(4‐chlorophenyl)‐1,3‐
thiazol‐4‐yl]methylsulfanyl]‐4‐[4‐(2‐hydroxyethoxy)phenyl]pyridine‐3,5‐
dicarbonitrile (capadenoson) was purchased fromHaoyuan Chemexpress
(Cat# HY‐14917; Shanghai, China).
The fluorescent A1‐receptor antagonist, CA200645, was pur-
chased from Hello Bio (Cat# HB7812; Bristol, UK). The fluorescent
A1‐receptor agonist, ABA‐X‐BY630 (Briddon et al., 2004), waspurchased from CellAura Technologies Ltd. (Nottingham, UK). The
fluorescent A1‐receptor agonist, ABEA‐X‐BY630, was synthesized as
previously described by Middleton et al. (2007). The fluorescent A1‐
receptor agonist, BY630‐X‐(D)‐A‐(D)‐A‐G‐ABEA, was synthesized as
described by Stoddart, Vernall, et al. (2015). Fugene HD transfection
reagent and furimazine were from Promega (Southampton, UK). All
other reagents were from Sigma‐Aldrich (Gillingham, UK).2.7 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org/, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY (Harding et al., 2018), and are permanently archived in
the Concise Guide to PHARMACOLOGY 2017/18 (Alexander
et al., 2017).3 | RESULTS
3.1 | Measurement of the specific binding of
CA200645 to rat and human adenosine A1‐receptors
using NanoBRET
We have recently described a bioluminescence energy transfer
approach (NanoBRET) to monitor ligand–receptor interactions in living
HEK293T cells expressing the human A1‐receptor tagged on its N‐
terminus with the luminescence protein Nluc (Stoddart, Johnstone,
et al., 2015). Here, we have compared the ligand‐binding characteris-
tics of Nluc‐tagged human and rat adenosine A1‐receptors using the
fluorescent antagonist ligand CA200645 (Stoddart, Johnstone, et al.,
2015). Binding experiments were performed over a large range of con-
centrations of CA200645 (1–500 nM) and yielded clear saturable
components of specific binding for both species receptor homologues
with negligible non‐specific binding detected in the presence of a high
concentration of the A1‐receptor selective antagonist DPCPX (1 μM).
The KD values obtained for CA200645 for the specific binding compo-
nent were 33.84 ± 10.15 nM (n = 6) and 35.44 ± 4.66 nM (n = 6) for
the human and rat Nluc‐A1‐receptors, respectively.3.2 | Inhibition of binding by A1‐receptor ligands
The binding affinities of non‐fluorescent A1‐receptor ligands at the
two species homologues were then determined from competition‐
binding studies in the presence of 25 nM CA200645 (Table 1).
Capadenoson, CCPA, NECA, and adenosine (Figure 1) showed similar
affinities between the two species (Table 1), with capadenoson being
the highest affinity agonist in both species. The selective A1‐recep-
tor antagonist DPCPX was a potent inhibitor of CA200645 binding
and exhibited a higher affinity for the rat A1‐receptor (Table 1). In
contrast, the antagonist MRS1220, the allosteric ligand VCP171
and VCP746 (a hybrid molecule made up of adenosine and
TABLE 1 Binding affinities of nine competing ligands determined from inhibition of the specific binding of CA200645 at the human Nluc‐A1AR
and rat Nluc‐A1AR
Nluc‐human A1AR Nluc‐rat A1AR
pIC50 ± SEM pKi ± SEM N pIC50 ± SEM pKi ± SEM N
Adenosine 4.17 ± 0.08 4.41 ± 0.08 6 4.27 ± 0.08 4.53 ± 0.08 5
Capadenoson 6.61 ± 0.12 6.85 ± 0.12 6 6.73 ± 0.11 6.99 ± 0.11 5
NECA 5.26 ± 0.17 5.50 ± 0.17 6 5.12 ± 0.04 5.39 ± 0.04 5
CCPA 6.15 ± 0.05 6.40 ± 0.05a 12 6.32 ± 0.04 6.58 ± 0.04 10
PD 81,723 3.99 ± 0.24 4.23 ± 0.24 6 <4 n.d. 5
VCP171 4.39 ± 0.09 4.63 ± 0.09a 6 3.89 ± 0.14 4.15 ± 0.14 5
VCP746 5.25 ± 0.09 5.49 ± 0.09a 6 4.76 ± 0.05 5.02 ± 0.06 5
DPCPX 7.89 ± 0.0.7 8.13 ± 0.07a 6 8.38 ± 0.15 8.64 ± 0.15 5
MRS1220 6.42 ± 0.07 6.66 ± 0.07a 6 5.71 ± 0.24 5.97 ± 0.24 5
Note. Data are expressed as mean ± SEM in n separate experiments, performed in triplicate. pKi values were determined from IC50 values using the Cheng–
Prusoff equation.
apKi values obtained of competing ligand significantly differ between human Nluc‐A1R and rat Nluc‐A1R (*P < 0.05; unpaired t test).
FIGURE 1 Chemical structures of VCP171,
PD 81,723, and A1‐receptor agonists
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human A1‐receptor (Table 1). The other allosteric ligand studied,
PD 81,723, was generally a weak direct inhibitor of the binding of
CA200645 in both species (Table 1).3.3 | Allosteric regulation of the inhibition of
fluorescent A1‐receptor antagonist binding by A1‐
receptor agonists
To investigate the potential for PD 81,723 and VCP171 (Figure 1) to
regulate A1‐receptor agonist binding to the human and rat A1‐recep-
tors in living cells, we evaluated the effect co‐incubation withincreasing concentrations of VCP171 or PD 81,723 on the ability
of adenosine, NECA, CCPA, and capadenoson to inhibit the specific
binding of CA200645 to Nluc‐tagged A1‐receptors. PD 81,723 used
at concentrations of 3, 10, or 30 μM shifted the agonist competition
curves to the left and produced a decrease in the IC50 values for
adenosine, CCPA, and NECA binding to the human A1‐receptor
(Figure 2a,c,d; Table 2), without markedly changing the direct binding
of CA200645 alone (Figure 2a,c,d). Significant effects on IC50 values
were observed with 10 μM PD 81,723 for NECA and 30 μM PD
81,723 for adenosine and CCPA (Table 2). A smaller effect was
observed on the A1‐receptor selective agonist capadenoson
(Albrecht‐Kupper, Leineweber, & Nell, 2012; Tendera et al., 2012),
and higher concentrations of PD 81,723 (that also had a direct
FIGURE 2 Effect of PD 81,723 and VCP171 on agonist binding to the human Nluc‐A1R. The effect of the allosteric modulators PD 81,723 and
VCP171 on the ability of adenosine A1‐receptor agonists (adenosine, capadenoson, CCPA, and NECA) to inhibit CA200645 (25 nM) binding was
monitored using BRET. (a) Adenosine and PD 81,723; (b) capadenoson and PD 81,723; (c) NECA and PD 81,723; (d) CCPA and PD 81,723; (e)
adenosine and VCP171; (f) capadenoson and VCP171; (g) NECA and VCP171; and (h) CCPA and VCP171. Figures shown are single representative
experiments from five (a, c, g) or six (b, d–f, h) separate experiments that were each performed in triplicate. Data are expressed as mean ± SEM of
the triplicate data
6 COOPER ET AL.BJPinhibitory effect on the binding of CA200656 alone) were required
to produce a significant change (Figure 2b; Table 2).
In the case of VCP171, 3, 10, or 30 μM concentrations of this
allosteric regulator not only produced a clearer decrease in the specific
binding of CA200645 alone to the human A1‐receptor but also pro-
duced significant decreases in the IC50 for adenosine, CCPA, and
NECA (Figure 2e,g,h; Table 2) without producing a significant change
in the IC50 of capadenoson (Figure 2f; Table 2).At the rat A1‐receptor, PD 81,723 (3, 10, or 30 μM) did not sig-
nificantly alter the IC50 values for inhibition of specific CA200645
binding of adenosine, NECA, or capadenoson (Figure 3a,b,c;
Table 2), although there was a tendency to produce a small decrease
in IC50 for adenosine and NECA (Table 2). There was, however, a
significant effect on the IC50 value of CCPA at 10 and 30 μM PD
81,723 (Table 2; Figure 3d). In contrast, VCP171 (10 or 30 μM) sig-
nificantly decreased the IC50 values of CCPA, NECA, and to a lesser
TABLE 2 The effect of three different concentrations of allosteric modulator (PD 81,723 or VCP171) on agonist (adenosine, capadenoson,
NECA, and CCPA) pIC50 values, determined by the inhibition of CA200645 specific binding of at the human or rat Nluc‐A1‐AR
Species
PD 81,723 VCP171
0 3 μM 10 μM 30 μM 0 3 μM 10 μM 30 μM
Adenosine Human 4.18 ± 0.11 4.36 ± 0.14 4.66 ± 0.12 5.07 ± 0.18* 4.23 ± 0.06 4.38 ± 0.06 4.77 ± 0.09* 5.05 ± 0.13*
NECA Human 5.21 ± 0.08 5.21 ± 0.10 5.72 ± 0.08* 5.99 ± 0.09* 5.37 ± 0.06 5.68 ± 0.05* 5.96 ± 0.04* 6.00 ± 0.05*
CCPA Human 6.15 ± 0.09 6.29 ± 0.10 6.49 ± 0.12 6.75 ± 0.08* 6.14 ± 0.10 6.47 ± 0.06* 6.68 ± 0.07* 6.80 ± 0.09*
Capadenoson Human 6.55 ± 0.10 6.67 ± 0.07a 6.84 ± 0.08b 6.94 ± 0.06c* 6.63 ± 0.09 6.66 ± 0.09 6.71 ± 0.08 6.63 ± 0.07
Adenosine Rat 4.61 ± 0.37 4.74 ± 0.22 4.85 ± 0.27 5.12 ± 0.35 4.13 ± 0.08 4.66 ± 0.28 5.14 ± 0.15* 4.99 ± 0.28
NECA Rat 5.43 ± 0.19 5.50 ± 0.23 5.70 ± 0.35 6.00 ± 0.31 5.03 ± 0.10 5.62 ± 0.16 5.95 ± 0.20* 6.13 ± 0.23*
CCPA Rat 6.28 ± 0.05 6.43 ± 0.03* 6.70 ± 0.02* 6.91 ± 0.04* 6.35 ± 0.07 6.78 ± 0.03* 7.06 ± 0.03* 6.96 ± 0.10*
Capadenoson Rat 6.56 ± 0.16 6.54 ± 0.12 6.74 ± 0.17 6.71 ± 0.11 6.60 ± 0.07 6.76 ± 0.14 6.79 ± 0.15 6.84 ± 0.16
Note. Data are expressed as mean ± SEM in separate experiments (n = 5 or 6), performed in triplicate.
a25 μM PD 81,723.
b50 μM PD 81,723.
c100 μM PD 81,723.
*P < 0.05, compared to 0 allosteric modulator; one‐way ANOVA, post hoc Tukey's test.
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agonist response to capadenoson (Figure 3f; Table 2).3.4 | Allosteric effect on the specific binding of
fluorescent A1‐receptor agonists
To establish whether a direct action of allosteric regulators could be
demonstrated on the binding of fluorescent agonists to the A1‐recep-
tor in living cells, we investigated their effect on the binding of the
adenosine based fluorescent ligand ABA‐X‐BY630 and two NECA‐
based fluorescent derivatives: ABEA‐X‐BY630 and its tripeptide linker
variant BY630‐X‐Ala‐Ala‐Gly‐ABEA (AAG‐ABEA‐X‐BY630; Figure 4).
ABA‐X‐BY630 is an effective agonist at A1‐receptors in mediating
inhibition of CRE‐mediated gene expression, calcium mobilization,
and ERK1/2 phosphorylation (Briddon et al., 2004; May et al., 2010).
Similarly, ABEA‐X‐BY630 and AAG‐ABEA‐X‐BY630 have been shown
to be full agonists of A1‐receptor‐mediated inhibition of forskolin‐
stimulated cAMP accumulation or CRE‐mediated gene expression
respectively (Middleton et al., 2007; Stoddart, Vernall, et al., 2015).
VCP171 produced a significant increase in the specific binding
of the adenosine analogue ABA‐X‐BY630 to both the human
(Figure 5a) and rat A1‐receptors (Figure 5c). Partial F test analysis
of the non‐linear regression fits to the combined data shown in
Figure 3 confirmed that the two binding parameters (pKD and Bmax)
differed significantly between the control and VCP171 (10 or
30 μM) curves (i.e., they could not be shared; Figure 5a,c). In the
case of the human receptor, this could also be ascribed to a signifi-
cant change in the Bmax value (partial F test). Analysis of the mean
parameters from the individual repeat experiments (Tables 3 and 4)
confirmed a significant increase in Bmax and pKD values for the
human (Table 3) but not the rat A1‐receptor (Table 4). Smaller but
still significant increases (partial F test) in specific binding of ABA‐
X‐BY630 were also observed with PD 81,723 in the human(Figure 5b) and rat (Figure 5d). However, neither effect could be
reliably ascribed to a change in an individual binding parameter (Bmax
or pKD). From the analysis of individual experiments, a significant
change was only observed in pKD of the rat A1‐receptor at 10 μM
PD 81,723 (Table 4).
In the case of the NECA derivative ABEA‐X‐BY630, significant
increases in specific binding were detected with VCP171 at both A1‐
receptor species homologues (Figure 6a,c). At the human A1‐receptor,
this was due to significant changes in both pKD and Bmax (Table 3),
whereas for the rat homologue, it was more dependent upon an
increase in Bmax (Table 4). PD 81,723 did not significantly change
any of the binding parameters for the human (Table 3) or rat
(Table 4) A1‐receptors, but there was a very small elevation in overall
specific binding at the human A1‐receptor but not the rat (Figure 6b,d).
For the tripeptide linker variant of ABEA‐X‐BY630 (AAG‐ABEA‐X‐
BY630) a similar profile was observed to that obtained with ABEA‐X‐
BY630. Significant increases in specific binding were detected with
VCP171 at both A1‐receptor species homologues (Figure 7a,c). At the
human A1‐receptor, this appeared to be due to significant changes in
both pKD and Bmax (Table 3); although for the rat homologue, this was
more dependent on an increase in pKD (Table 4). F test analysis of
the combined data for the human A1‐receptor also indicated an effect
of VCP171 on pKD (Figure 7a). In the case of PD 81,723, no consistent
of effect of this allosteric enhancer was observed on AAG‐ABEA‐X‐
BY630 binding in the rat although a small significant increase in
overall specific binding was detectable at the human A1‐receptor.4 | DISCUSSION
The data presented here have demonstrated the utility of the
NanoBRET ligand binding approach to study species differences in
the binding of agonists and antagonists to the adenosine A1‐receptor
in intact living cells. The requirement of NanoBRET for close proximity
FIGURE 3 Effect of PD 81,723 and VCP171 on agonist binding to the rat Nluc‐A1R. The effect of the allosteric modulators PD 81,723 and
VCP171 on the ability of adenosine A1‐receptor agonists (adenosine, capadenoson, CCPA, and NECA) to inhibit CA200645 (25 nM) binding
was monitored using BRET. (a) Adenosine and PD 81,723; (b) capadenoson and PD 81,723; (c) NECA and PD 81,723; (d) CCPA and PD81,723; (e)
adenosine and VCP171; (f) capadenoson and VCP171; (g) NECA and VCP171; and (h) CCPA and VCP171. Figures shown are single representative
experiments from five (a–f, h) or six (g) separate experiments that were each performed in triplicate. Data are expressed as mean ± SEM of the
triplicate data
8 COOPER ET AL.BJPbetween the N‐terminal Nluc tag of the receptor and the receptor‐
bound fluorescent antagonist CA200645 (~10 nm) produced low
levels of non‐specific binding of CA200645 in both species that was
consistent with our previous work (Stoddart, Johnstone, et al., 2015).
This enabled accurate determination of the binding affinities of com-
peting A1‐receptor ligands to be made. This work confirmed the spe-
cies differences in the affinity of DPCPX reported previously in brain
membrane homogenates between the human and rat A1‐receptorhomologues (Maemoto et al., 1997). Interestingly, the allosteric
regulators PD 81,723 and VCP171 produced a small direct inhibition
of CA200645 binding at high concentrations (>100 μM for PD
81,723 and 10–100 μM VCP171) that was more evident at the human
A1‐receptor.
The most striking effects of PD 81,723 and VCP171, however,
were that they significantly enhanced the binding affinities of NECA,
CCPA, and adenosine to the human A1‐receptor, as determined from
FIGURE 5 Effect of VCP171 and PD 81,723
on the binding of ABA‐X‐BY630 (ABA) to the
human and rat adenosine A1‐receptors. Effect
of VCP171 (a, c) or PD 81,723 (b, d) on the
binding of ABA‐X‐BY630 to the human (a, b)
or rat (c, d) A1‐receptors. Figures show
combined data from five separate
experiments (each performed in triplicate).
Data are expressed as mean ± SEM. *P < 0.05
fitted parameters (both KD and Bmax) curves
significantly different from control (without
allosteric modulator; partial F test). #P < 0.05
fitted parameter for Bmax significantly
different from control (partial F test)
TABLE 3 The effect of three different concentrations of allosteric modulator (PD 81,723 or VCP171) on the binding of the fluorescent agonists
ABA‐X‐BY630, ABEA‐X‐BY630, and BY630‐X‐AAG‐ABEA to the human Nluc‐A1AR
Human Nluc A1R
VCP171 PD 81,723
Fluorescent ligand pKD or Bmax 0 10 μM 30 μM N 0 10 μM 30 μM N
ABA‐X‐BY630 pKD 6.23 ± 0.05 6.44 ± 0.08* 6.46 ± 0.05* 5 6.11 ± 0.02 6.15 ± 0.09 6.11 ± 0.20 5
ABA‐X‐BY630 Bmax 0.019 ± 0.002 0.033 ± 0.004* 0.036 ± 0.003* 5 0.019 ± 0.002 0.035 ± 0.005 0.035 ± 0.008 5
ABEA‐X‐BY630 pKD 5.99 ± 0.15 6.43 ± 0.05* 6.43 ± 0.08* 6 6.01 ± 0.15 5.96 ± 0.11 5.94 ± 0.19 5
ABEA‐X‐BY630 Bmax 0.006 ± 0.001 0.013 ± 0.002* 0.016 ± 0.002* 6 0.007 ± 0.001 0.012 ± 0.003 0.016 ± 0.004 5
BY630‐X‐AAG‐ABEA pKD 6.17 ± 0.16 6.97 ± 0.16* 6.97 ± 0.15* 6 6.11 ± 0.20 6.35 ± 0.17 6.49 ± 0.16 5
BY630‐X‐AAG‐ABEA Bmax 0.019 ± 0.001 0.021 ± 0.001 0.024 ± 0.001* 6 0.021 ± 0.003 0.022 ± 0.002 0.24 ± 0.002 5
Note. pKD and Bmax values were obtained from individual experiments. Data are expressed as mean ± SEM obtained in N separate experiments. Each indi-
vidual experiment was performed in triplicate.
*P < 0.05, compared to 0 allosteric modulator; one‐way ANOVA, post hoc Tukey's test.
FIGURE 4 Chemical structure of three
fluorescent agonists (BY630‐X‐ABA, BY630‐
X‐ABEA, and BY630‐Ala‐Ala‐Gly‐ABEA) and
the fluorescent antagonist CA200645
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TABLE 4 The effect of three different concentrations of allosteric modulator (PD 81,723 or VCP171) on the binding of the fluorescent agonists
ABA‐X‐BY630, ABEA‐X‐BY630, and BY630‐X‐AAG‐ABEA to the rat Nluc‐A1AR
Rat Nluc A1R
VCP171 PD 81,723
Fluorescent ligand pKD or Bmax 0 10 μM 30 μM N 0 10 μM 30 μM N
ABA‐X‐BY630 pKD 6.05 ± 0.30 6.31 ± 0.18 6.16 ± 0.19 5 6.02 ± 0.14 6.25 ± 0.07 6.33 ± 0.11 5
ABA‐X‐BY630 Bmax 0.031 ± 0.014 0.048 ± 0.009 0.072 ± 0.021 5 0.031 ± 0.002 0.040 ± 0.005 0.054 ± 0.007* 5
ABEA‐X‐BY630 pKD 6.05 ± 0.19 6.18 ± 0.08 6.22 ± 0.07 5 5.74 ± 0.14 5.86 ± 0.13 5.83 ± 0.22 6
ABEA‐X‐BY630 Bmax 0.010 ± 0.001 0.021 ± 0.002* 0.026 ± 0.003* 5 0.015 ± 0.002 0.018 ± 0.002 0.032 ± 0.01 6
BY630‐X‐AAG‐ABEA pKD 5.75 ± 0.17 6.60 ± 0.12* 6.49 ± 0.15* 5 5.79 ± 0.07 5.74 ± 0.15 6.01 ± 0.07 5
BY630‐X‐AAG‐ABEA Bmax 0.026 ± 0.003 0.023 ± 0.003 0.034 ± 0.005 5 0.016 ± 0.002 0.038 ± 0.008 0.036 ± 0.007 5
Note. pKD and Bmax values were obtained from individual experiments. Data are expressed as mean ± SEM obtained in N separate experiments. Each indi-
vidual experiment was performed in triplicate.
*P < 0.05 compared to 0 allosteric modulator; one‐way ANOVA, post hoc Tukey's test.
FIGURE 6 Effect of VCP171 and PD 81,723
on the binding of ABEA‐X‐BY630 (ABEA) to
the human and rat adenosine A1‐receptors.
Effect of VCP171 (a, c) or PD 81,723 (b, d) on
the binding of ABEA‐X‐BY630 to the human
(a, b) or rat (c, d) A1‐receptors. Figures show
combined data from six (a, d) or five (b, c)
separate experiments (each performed in
triplicate). Data are expressed as mean ± SEM.
*P < 0.05 fitted parameters (both KD and Bmax)
curves significantly different from control
(without allosteric modulator; partial F test)
10 COOPER ET AL.BJPinhibition of the specific binding of CA200645 in whole cells. This was
generally achieved at lower concentrations of the allosteric modulator
(3–30 μM) than were required to directly inhibit the specific binding of
CA200645. At the rat A1‐receptor, the effect of PD 81,723 on the
binding affinity of adenosine and NECA was less marked and did not
reach statistical significance at the concentrations tested (3–30 μM).
Significant increases in the binding affinity of CCPA were, however,
observed with PD 81,723 at the rat A1‐receptor. In contrast,
VCP171 (10 and 30 μM) enhanced adenosine, CCPA, and NECA bind-
ing at the rat A1‐receptor. Interestingly, both modulators (3–30 μM)
had no significant effect on the binding affinity of the selective
A1‐receptor partial agonist capadenoson (Albrecht‐Kupper et al.,
2012; Tendera et al., 2012), although a small effect of PD 81,723
was evident at the human receptor if the concentration of PD
81,723 was raised to 100 μM.This apparent probe dependence is a classical feature of allosteric
interactions and is consistent with VCP171 and PD 81,723 binding to
a topographically distinct allosteric site on the A1‐receptor from which
they can elicit conformational changes that lead to an alteration in the
binding affinity of an agonist ligand occupying the classical orthosteric
binding site (Kenakin, 2009; Keov, Sexton, & Christopoulos, 2010;
Kruse et al., 2013; May, Leach, Sexton, & Christopoulos, 2007). How-
ever, taken together, the data suggest that both PD 81,723 and
VCP171 can bind to both this allosteric site (leading to enhanced ago-
nist binding) and, at higher concentrations, to the orthosteric ligand‐
binding site where they are responsible for inhibiting binding of the
fluorescent antagonist CA200645. Consistent with this latter observa-
tion, the recent crystal structure of the inactive human A1‐receptor
has shown that VCP171 can be docked into the orthosteric site and
its binding site overlaps with that of the classical A1‐receptor
FIGURE 7 Effect of VCP171 and PD 81,723 on the binding of BY630‐X‐(D)‐A‐(D)‐A‐G‐ABEA (AAG‐ABEA) to the human and rat adenosine A1‐
receptors. Effect of VCP171 (a, c) or PD 81,723 (b, d) on the binding of BY630‐X‐(D)‐A‐(D)‐A‐G‐ABEA to the human (a, b) or rat (b, d) A1‐receptors.
Figures show combined data from six (a) or five (b, c, d) separate experiments (each performed in triplicate). Data are expressed as mean ± SEM.
*P < 0.05 fitted parameters (both KD and Bmax) curves significantly different from control (without allosteric modulator; partial F test).
#P < 0.05
fitted parameter for KD significantly different from control (partial F test)
COOPER ET AL. 11BJPantagonist DPCPX (Glukhova et al., 2017). It was noticeable, however,
that these authors did also identify a putative secondary binding
pocket in this inactive A1‐receptor structure that could represent a
site that is involved in allosteric regulation (Glukhova et al., 2017).
A striking feature of the inactive human A1‐receptor crystal struc-
ture obtained in complex with the covalently bound antagonist DU‐
172 is that the ECL2 residues form an α‐helix that extends away from
the transmembrane regions of the receptor in a manner that is almost
perpendicular to the plane of the membrane (Glukhova et al., 2017;
Figure 8a). This is a region of the receptor that mutagenesis studies
have suggested is crucial to both the functional efficacy of the agonist
NECA (Nguyen, Baltos, et al., 2016) and to the ability of PD 81,723
and VCP171 to elicit allosteric effects on orthosteric agonist binding
(Nguyen, Vecchio, et al., 2016). It is therefore possible that ECL2
undergoes a conformational change following agonist binding to bring
these residues in closer juxtaposition to the large binding pocket of
the A1‐receptor that contains the orthosteric binding site (Glukhova
et al., 2017). However, the recent structure of the adenosine‐occupied
A1‐receptor in complex with a Gi‐protein (Figure 8b) suggests that
although the orthosteric binding cavity does collapse (and become
smaller) due to an inward movement of the extracellular domains of
transmembrane regions 1 and 2 (Figure 8c,d), the position of the
ECL2 remains largely unaltered (Draper‐Joyce et al., 2018; Figure 8c,
d). The reciprocal nature of the conformational interactions normallyobserved between allosteric and orthosteric sites also suggests that
an orthosteric agonist needs to be present for PD 81,723 and
VCP171 to bind with higher affinity to the allosteric site. Any differ-
ence in this effect between species is likely to be a consequence of
subtle differences in the conformational changes induced by
VCP171 and PD 81,723 in each species. This may be a consequence
of their ability to induce a collapse in the orthosteric binding cavity,
observed in the active crystal structure (R*), to different extents.
The lack of a significant effect of allosteric enhancers on the bind-
ing of the partial A1‐receptor agonist capadenoson also suggests a
reduced ability of this agonist to switch the receptor from R to R* or
indeed to produce a different “partially active” R* conformation.
Thus, for example, recent structural information published for the
β2‐adrenoceptor partial agonist salmeterol indicates subtle difference
in the hydrogen‐bonding interactions within the orthosteric binding
site for salmeterol and the full agonist adrenaline (Masureel et al.,
2018). The reciprocal nature of the conformational interactions
between allosteric and orthosteric sites would be consistent with
a reduced influence of allosteric enhancers on the binding of
capadenoson to the A1‐receptor.
Figure 9a shows how ECL2 differs between the two species and
also highlights those residues that have been implicated in the alloste-
ric effects of PD 81,723 or VCP171 on the binding of the agonist
NECA to the human A1‐receptor (Nguyen, Vecchio, et al., 2016). Also
FIGURE 8 Crystal structures of the human A1‐receptor bound to (a, c) the orthosteric antagonist DU172 (PDB: 5UEN; Glukhova et al., 2017) or
(b, d) bound to the endogenous agonist adenosine in the presence of a Gi‐α subunit (PDB: 6D9H; Draper‐Joyce et al., 2018). Structures show the
ligand binding pocket from a top‐down view. (c, d) Surface projection of the transmembrane helices, ECL1, ECL2, and ECL3 to demonstrate the
closing of the binding pocket in the agonist‐bound active structure (d) compared to the antagonist‐bound inactive structure (c). The orthosteric
(dashed red circle) and the position of the potential secondary allosteric binding site (dashed yellow circle) identified by Glukhova et al. (2017) in
the antagonist‐bound structure are also shown (c). These positions have also been extrapolated to the agonist‐bound structure (d). 3D structures
were produced using the programme PyMol (Schrodinger, Cambridge, MA, USA)
12 COOPER ET AL.BJPhighlighted is E172 that appears to be important for the direct binding
of PD 81,723 and VCP171 to the human A1‐receptor (Nguyen,
Vecchio, et al., 2016). It is notable that the mutations identified by
Nguyen, Baltos, et al. (2016) do not include residues that are different
between species. The amino acid sequence that represents the α‐helix
of EL2 in the human sequence is highlighted in grey in Figure 9a. Helix
prediction analysis using PredictProtein (Rost, Yachdav, & Liu, 2004)
confirmed that there was no change in helix propensity in the two
species and that the α‐helix is in the same position for the rat protein
sequence. It is notable that four of the five residues that are different
between rat and human A1‐sequence are in the α‐helical region. This
suggests that the M162V change (which is adjacent to the helix
domain and also to two residues mutated by Nguyen, Vecchio, et al.,
2016) may underlie some of the subtle changes in allosteric action
between the two species.
A direct effect of both VCP171 and PD 81,723 on agonist binding
was also evident from NanoBRET studies using fluorescent A1‐recep-
tor‐agonists. This was particularly clear for VCP171 where theallosteric modulator significantly increased the level of specific binding
of all three fluorescent agonists tested at the human A1‐receptor. This
was a consequence of both an increase in maximal binding capacity
(Bmax) and affinity (pKD). Consistent with this positive allosteric effect,
we have previously shown that PD 81,723 (10 μM) can slow the dis-
sociation of BY630‐ABA from human A1‐receptors expressed in
CHO cells (May et al., 2010). The effect of VCP171 was, however, also
species dependent with an increase in both binding parameters evi-
dent with all three fluorescent agonists at the human A1‐receptor,
but the effects were limited to Bmax (ABEA‐X‐BY630) and pKD
(AAG‐ABEA‐X‐BY650) for particular fluorescent agonists at the rat
species homologue. It is also worth pointing out that our results sug-
gest that the functionalization and addition of fluorophore to the ago-
nist chemical scaffold has been achieved at a point that does not clash
with the allosteric modulator binding site.
The data obtained with VCP171 at the human A1‐receptor are
consistent with an increase in the proportion of a higher affinity ago-
nist conformation (R*; Figure 9c) that was only detectable with
FIGURE 9 (a) Amino acid sequence of extracellular loop 2 (ECL2) of the human (Hu) A1‐receptor showing those residues suggested by
mutagenesis studies (Nguyen, Vecchio, et al., 2016) to be involved in the allosteric effects on the binding of NECA of PD 81,723 (red circles)
and VCP171 (blue circles). The helical region is highlighted in grey. E172 (green circle) is also indicated. The amino acids that differ between the
human and rat ECL2 sequences are also highlighted (blue letters). (b) Crystal structure of the human A1‐receptor bound to the orthosteric
antagonist DU172 (PDB: 5UEN; Glukhova et al., 2017) with both orthosteric and putative allosteric binding sites shown. (c) Crystal structure of
the human A1‐receptor bound to the endogenous agonist adenosine (PDB: 6D9H; Draper‐Joyce et al., 2018) with orthosteric and allosteric
binding sites shown. Note the allosteric binding site in (c) and does not overlap with the orthosteric binding site. 3D structures were produced
using the program PyMol (Schrodinger, Cambridge, MA, USA)
COOPER ET AL. 13BJPfluorescent A1‐receptor agonists. That is, these fluorescent analogues
of adenosine and NECA have a lower affinity for the antagonist‐bound
conformation of the receptor (R; Figure 9b) and do not detect binding
to this conformation at the concentrations used in the present fluores-
cent agonist‐binding studies. The difference in the extent to which
VCP171 and PD 81,723 enhance fluorescent agonist‐binding Bmax
values might also suggest that this property underlies the ability of
allosteric enhancers to produce direct agonist actions in the absence
of orthosteric agonists (Nguyen, Vecchio, et al., 2016). Thus, the
increased formation of active receptor conformations (R*) in the pres-
ence of the allosteric regulator may lead to increased stimulation of
intracellular signalling pathways. An increased conversion of inactive
receptor (R) to active receptor conformations (R*) by VCP171 and
PD 81,723 may also explain the decrease in specific binding of the
fluorescent antagonist CA200645 observed above, although the
structure of the inactive receptor also indicates that the allosteric
ligands can bind to the orthosteric binding site (Glukhova et al., 2017).
In summary, the present study has shown that PD 81,723 and
VCP171 can elicit positive allosteric effects on the binding affinity of
orthosteric agonists at both the rat and human adenosine A1‐recep-
tors. This work also confirms that these two allosteric regulators
exhibit both probe and species homologue dependence. Thus, the
allosteric effect on the highly selective partial agonist capadenoson
is much less marked than for the full agonists NECA and adenosine
in both species. In addition, at higher concentrations, both allosteric
regulators have a direct inhibitory effect on the binding of the
orthosteric fluorescent antagonist CA200645 that is consistent withthe suggestion from crystallographic studies that indicates that they
can also bind directly to the orthosteric binding site of the A1‐recep-
tor. Finally, VCP171 and, to a lesser extent, PD 81,723, were also able
to increase the specific binding of three fluorescent A1‐receptor ago-
nists in a species‐dependent manner that involved increases in Bmax
and pKD. This latter effect may provide new insights into the mecha-
nisms by which allosteric enhancers can elicit functional responses in
the absence of orthosteric A1‐receptor agonists.ACKNOWLEDGEMENTS
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